RNAi Co., Ltd. (RCL) Licenses MetaCore(TM) From GeneGo and Collaborates in Platform Development

RNAi Co., Ltd. (RCL) Licenses MetaCore(TM) From GeneGo and Collaborates in Platform Development ST. JOSEPH, Mich., Jan. 24 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that RCL has licensed MetaCore(TM) for its RNA interference drug discovery efforts. MetaCore(TM) is an integrated platform for the analysis of different types of experimental data in drug discovery. MetaCore(TM) applies a proprietary, manually curated, human protein interaction and pathway database to drug discovery. The flexible database architecture enables straightforward integration of in house and third party software and databases. MetaCore(TM) also has easy to use software for building, visualization and analysis of tissue specific biological networks with and without experimental data. "We looked at several systems biology packages and found that MetaCore(TM) suited our needs the best," said Mr.Yukikazu Natori, Chairman of RNAi. "The system is flexible for customization, and the GeneGo team is open minded for collaborative development. We needed a flexible partner that was willing to integrate with our current siRNA technology." "We welcome RCL as our first Japanese customer," said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo. "RCL has built an impressive and unique technology portfolio in the RNA interference area. Their findings are very synergistic with pathway analysis of complex diseases we are working on. We consider this agreement as the first step in long term collaboration in the intersection of these two exciting technologies." About GeneGo GeneGo is a Michigan-based company developing systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, phenotypic data etc.) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo's flagship product, MetaCore(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism and toxicity for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore(TM). For more information, please visit the company's web site at www.genego.com. MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc. About RNAi RCL (www.rnai.co.jp) is a biotechnology company in the field of functional genomics based on RNA interference. RCL conducts two types of business. One is research support business for life science and the other is drug discovery business. RCL's unparallel RNA interference science and technology achieves high specificity of gene knock-down while minimizing unwanted off-target effects. RCL has already identified and applied the patent about 820,000 kinds of siRNA/shRNA/Oligo interference for all of human and mice genes known publicly. RCL's licensees can access to the most comprehensive RNAi design system, siDirect(TM) with usage of 820,000 sequences and get high-quality chemically synthetic siRNA manufactured by Proligo, siPerfect(TM) at the most attractive price in the market. RCL currently has two business offices and a wet lab and a dry lab in Japan with 20 employees and plans to enhance GMP functionality for preclinical study this year. Source: GeneGo, Inc. CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo, Inc., +1-858-756-7996, julie@genego.com Web site: http://www.rnai.co.jp/ Web site: http://www.genego.com/ ------- Profile: International Entertainment